Cell-traversal protein for ookinetes and sporozoites (CelTOS) formulated with potent TLR adjuvants induces high-affinity antibodies that inhibit Plasmodium falciparum infection in Anopheles stephensi

Heterogeneity in the acquisition of naturally acquired antibodies to cell-traversal protein for ookinetes and sporozoites (CelTOS) and thrombospondin-related adhesion protein (TRAP) of Plasmodium falciparum in naturally infected patients from unstable malaria areas in Iran

(2018) Sakineh Pirahmadi et al.   ACTA TROPICA

malERA: An updated research agenda for diagnostics, drugs, vaccines, and vector control in malaria elimination and eradication

(2017)   PLOS MEDICINE

The Plasmodium falciparum Cell-Traversal Protein for Ookinetes and Sporozoites as a Candidate for Preerythrocytic and Transmission-Blocking Vaccines

(2016) Diego A. Espinosa et al.   INFECTION AND IMMUNITY

Malaria parasite CelTOS targets the inner leaflet of cell membranes for pore-dependent disruption

(2016) John R Jimah et al.   eLife

HIV Envelope Trimer Specific Immune Response Is Influenced by Different Adjuvant Formulations and Heterologous Prime-Boost

(2016) Juliana de Souza Apostólico et al.   PLoS One

Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults

(2016) Kawsar R. Talaat et al.   PLoS One

Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial

(2015)   LANCET

Discovery of Novel Plasmodium falciparum Pre-Erythrocytic Antigens for Vaccine Development

(2015) Joao C. Aguiar et al.   PLoS One

Recent advances in recombinant protein-based malaria vaccines

(2015) Simon J. Draper et al.   VACCINE

Malaria vaccine candidate antigen targeting the pre-erythrocytic stage ofPlasmodium falciparumproduced at high level in plants

(2014) Nadja Voepel et al.   Biotechnology Journal

Combinatorial Immunotherapy of Polyinosinic–Polycytidylic Acid and Blockade of Programmed Death-Ligand 1 Induce Effective CD8 T-cell Responses against Established Tumors

(2014) Toshihiro Nagato et al.   CLINICAL CANCER RESEARCH

The path of malaria vaccine development: challenges and perspectives

(2014) C. Arama et al.   JOURNAL OF INTERNAL MEDICINE

Malaria vaccine technology roadmap

(2013) Vasee S Moorthy et al.   LANCET

Immune mechanisms in malaria: new insights in vaccine development

(2013) Eleanor M Riley et al.   NATURE MEDICINE

Computational and Experimental Validation of B and T-Cell Epitopes of the In Vivo Immune Response to a Novel Malarial Antigen

(2013) Elke S. Bergmann-Leitner et al.   PLoS One

Malaria vaccine R&D in the Decade of Vaccines: Breakthroughs, challenges and opportunities

(2013) Ashley J. Birkett et al.   VACCINE

Targeting the Non-structural Protein 1 from Dengue Virus to a Dendritic Cell Population Confers Protective Immunity to Lethal Virus Challenge

(2013) Hugo R. Henriques et al.   PLoS Neglected Tropical Diseases

Self-Adjuvanting Bacterial Vectors Expressing Pre-Erythrocytic Antigens Induce Sterile Protection Against Malaria

(2013) Elke S. Bergmann-Leitner et al.   Frontiers in Immunology

Effects on Immunogenicity by Formulations of Emulsion-Based Adjuvants for Malaria Vaccines

(2012) Christopher B. Fox et al.   Clinical and Vaccine Immunology

Polyinosinic-Polycytidylic Acid Limits Tumor Outgrowth in a Mouse Model of Metastatic Lung Cancer

(2012) G. Forte et al.   JOURNAL OF IMMUNOLOGY

Trends in vaccine adjuvants

(2011) Virgil EJC Schijns et al.   Expert Review of Vaccines

Immune responses elicited by co-immunization of Plasmodium vivax and P. falciparum MSP-1 using prime-boost immunization strategies

(2011) A. A. MEHRIZI et al.   PARASITE IMMUNOLOGY

Cellular and humoral immune effector mechanisms required for sterile protection against sporozoite challenge induced with the novel malaria vaccine candidate CelTOS

(2011) Elke S. Bergmann-Leitner et al.   VACCINE

A Research Agenda for Malaria Eradication: Vaccines

(2011)   PLOS MEDICINE

A Research Agenda to Underpin Malaria Eradication

(2011) Pedro L. Alonso et al.   PLOS MEDICINE

New adjuvants for human vaccines

(2010) M Lamine Mbow et al.   CURRENT OPINION IN IMMUNOLOGY

Use of defined TLR ligands as adjuvants within human vaccines

(2010) Malcolm S. Duthie et al.   IMMUNOLOGICAL REVIEWS

Cutting Edge: Priming of CD8 T Cell Immunity to Herpes Simplex Virus Type 1 Requires Cognate TLR3 Expression In Vivo

(2010) Gayle M. Davey et al.   JOURNAL OF IMMUNOLOGY

Immunization with Pre-Erythrocytic Antigen CelTOS from Plasmodium falciparum Elicits Cross-Species Protection against Heterologous Challenge with Plasmodium berghei

(2010) Elke S Bergmann-Leitner et al.   PLoS One

Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and αDEC-CSP in non human primates

(2010) Kavita Tewari et al.   VACCINE

The RTS,S malaria vaccine

(2010) Sofia Casares et al.   VACCINE

Toward the Rational Design of a Malaria Vaccine Construct Using the MSP3 Family as an Example: Contribution of Immunogenicity Studies in Models

(2009) L.-J. Daher et al.   INFECTION AND IMMUNITY

Dendritic cells require a systemic type I interferon response to mature and induce CD4+Th1 immunity with poly IC as adjuvant

(2009) M. Paula Longhi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Therapeutic Targeting of Toll-Like Receptors for Infectious and Inflammatory Diseases and Cancer

(2009) L. A. J. O'Neill et al.   PHARMACOLOGICAL REVIEWS

The World Health Organization and global smallpox eradication

(2008) S Bhattacharya   JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH

The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine

(2008) C. Trumpfheller et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA